Vallis Capital Partners announces a full exit on CGC Genetics investment


Vallis Capital Partners announces that it has reached an agreement to sell CGC Genetics, a leading Medical Genetics Laboratory company serving customers in more than 65 countries, for an undisclosed amount to Unilabs, a Geneva based company.

CGC Genetics has grown to become one of the most advanced European Medical Genetics Laboratory providers, serving customers globally. The company is a reference for Medical Genetics testing, offering a full service of Medical Genetic testing solutions for its customers.

Jos Lamers, CEO of Unilabs said: “CGC has made an impressive journey to build its position as a pivotal player in the Medical Genetic Laboratory markets, with a worldwide footprint. This operation reflects our strategic focus on reinforcing Unilabs’ Reference and Special Testing Portfolio. We look forward to welcoming CGC Genetics into the Unilabs family.”

Eduardo Rocha, CEO of Vallis Capital Partners added: “We are very proud to have been part of the CGC Genetics success story since our Fund Vallis Sustainable Investments I invested in the company in 2014. Our chief strategic goal was to leverage the exceptional skill set of CGC Genetics which combined with the investment in state-of-the-art technology was the foundation for a growth cycle through international expansion. We are now confident that CGC Genetics will continue to thrive in a new growth cycle within the Unilabs environment.”

Prof. Purificação Tavares, CEO of CGC Genetics commented: “We believe we have found a true strategic partner in Unilabs, and I would like to thank Vallis Capital Partners for helping CGC Genetics getting to the next level. Within Unilabs we have a tremendous opportunity to accelerate our growth via the exchange of best practices and the support of an internationally recognised brand and contribute to expanding Unilabs’ capabilities for the benefit of all it’s customers.”